JP2013032353A5 - - Google Patents

Download PDF

Info

Publication number
JP2013032353A5
JP2013032353A5 JP2012152596A JP2012152596A JP2013032353A5 JP 2013032353 A5 JP2013032353 A5 JP 2013032353A5 JP 2012152596 A JP2012152596 A JP 2012152596A JP 2012152596 A JP2012152596 A JP 2012152596A JP 2013032353 A5 JP2013032353 A5 JP 2013032353A5
Authority
JP
Japan
Prior art keywords
salt
loxoprofen
pharmaceutical composition
carbinoxamine
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012152596A
Other languages
Japanese (ja)
Other versions
JP5433053B2 (en
JP2013032353A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2012152596A priority Critical patent/JP5433053B2/en
Priority claimed from JP2012152596A external-priority patent/JP5433053B2/en
Publication of JP2013032353A publication Critical patent/JP2013032353A/en
Publication of JP2013032353A5 publication Critical patent/JP2013032353A5/ja
Application granted granted Critical
Publication of JP5433053B2 publication Critical patent/JP5433053B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

カルビノキサミン又はその塩、及びジフェニルピラリン又はその塩からなる群より選ばれる1種以上と、ロキソプロフェン又はその塩とを実質的に互いに接しないように含有する医薬組成物。 Carbinoxamine or a salt thereof, and one or more members selected from the group consisting beauty diphenylpyraline or a salt thereof, pharmaceutical compositions containing such substantially contact with each other and loxoprofen or a salt thereof. ロキソプロフェン又はその塩が、ロキソプロフェンナトリウム水和物である請求項記載の医薬組成物。 Loxoprofen or a salt thereof, a pharmaceutical composition of claim 1 wherein the Loxoprofensodium hydrate. ロキソプロフェン又はその塩を、ロキソプロフェンナトリウム無水物換算で、10〜300mgを1日量として含有する請求項1又は2記載の医薬組成物。 The pharmaceutical composition according to claim 1 or 2 , wherein loxoprofen or a salt thereof is contained in an amount of 10 to 300 mg per day in terms of anhydrous loxoprofen sodium. カルビノキサミン又はその塩が、カルビノキサミンマレイン酸塩及びカルビノキサミンジフェニルジスルホン酸塩から選ばれる1種以上である請求項1〜3いずれか1項記載の医薬組成物。The pharmaceutical composition according to any one of claims 1 to 3, wherein the carbinoxamine or a salt thereof is one or more selected from carbinoxamine maleate and carbinoxamine diphenyl disulfonate. ジフェニルピラリン又はその塩が、ジフェニルピラリン塩酸塩及びジフェニルピラリンテオクル酸塩から選ばれる1種以上である請求項1〜4いずれか1項記載の医薬組成物。The pharmaceutical composition according to any one of claims 1 to 4, wherein the diphenylpyrine or a salt thereof is one or more selected from diphenylpyraline hydrochloride and diphenylpyraline theocuroate. カルビノキサミン又はその塩を、0.1〜60mgを1日量として含有する請求項1〜5いずれか1項記載の医薬組成物。The pharmaceutical composition according to any one of claims 1 to 5, comprising carbinoxamine or a salt thereof in an amount of 0.1 to 60 mg per day. ジフェニルピラリン又はその塩を、0.1〜13.5mgを1日量として含有する請求項1〜6いずれか1項記載の医薬組成物。The pharmaceutical composition according to any one of claims 1 to 6, comprising 0.1 to 13.5 mg of diphenylpyralin or a salt thereof as a daily dose. ジフェニルピラリン塩酸塩を、0.1〜12mgを1日量として含有する請求項5記載の医薬組成物。The pharmaceutical composition according to claim 5, which contains 0.1 to 12 mg of diphenylpyraline hydrochloride as a daily dose. ジフェニルピラリンテオクル酸塩を、0.1〜13.5mgを1日量として含有する請求項5記載の医薬組成物。The pharmaceutical composition according to claim 5, comprising diphenylpyraline theocuroate in an amount of 0.1 to 13.5 mg per day. ロキソプロフェン又はその塩が、ロキソプロフェン又はその塩を含有する粒状物である請求項1〜いずれか1項記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 to 9 , wherein loxoprofen or a salt thereof is a granular material containing loxoprofen or a salt thereof. カルビノキサミン又はその塩、及びジフェニルピラリン又はその塩からなる群より選ばれる1種以上が、カルビノキサミン又はその塩、及びジフェニルピラリン又はその塩からなる群より選ばれる1種以上を含有する粒状物である請求項1〜10いずれか1項記載の医薬組成物。One or more selected from the group consisting of carbinoxamine or a salt thereof and diphenylpyraline or a salt thereof is a granular material containing one or more selected from the group consisting of carbinoxamine or a salt thereof and diphenylpyraline or a salt thereof Item 11. A pharmaceutical composition according to any one of Items 1 to 10. (A)ロキソプロフェン若しくはその塩そのもの、又はロキソプロフェン若しくはその塩を含有する固形組成物と、(B)カルビノキサミン若しくはその塩そのもの、又はカルビノキサミン若しくはその塩を含有する固形組成物とを含有し、これらの固形組成物を構成する成分によって、ロキソプロフェン又はその塩とカルビノキサミン又はその塩とが互いに接しないように配置されている医薬組成物(但し、成分(A)がロキソプロフェン又はその塩そのものであり、かつ成分(B)がカルビノキサミン又はその塩そのものである場合を除く)。(A) Loxoprofen or a salt thereof, or a solid composition containing loxoprofen or a salt thereof, and (B) a solid composition containing carbinoxamine or a salt thereof, or a solid composition containing carbinoxamine or a salt thereof. A pharmaceutical composition in which loxoprofen or a salt thereof and carbinoxamine or a salt thereof are arranged so as not to contact each other depending on the components constituting the composition (provided that component (A) is loxoprofen or a salt thereof itself and the component ( Except when B) is carbinoxamine or a salt thereof). (A)ロキソプロフェン若しくはその塩そのもの、又はロキソプロフェン若しくはその塩を含有する固形組成物と、(B)ジフェニルピラリン若しくはその塩そのもの、又はジフェニルピラリン若しくはその塩を含有する固形組成物とを含有し、これらの固形組成物を構成する成分によって、ロキソプロフェン又はその塩とジフェニルピラリン又はその塩とが互いに接しないように配置されている医薬組成物(但し、成分(A)がロキソプロフェン又はその塩そのものであり、かつ成分(B)がジフェニルピラリン又はその塩そのものである場合を除く)。(A) Loxoprofen or a salt thereof itself, or a solid composition containing loxoprofen or a salt thereof, and (B) diphenylpyraline or a salt thereof, or a solid composition containing diphenylpyraline or a salt thereof, A pharmaceutical composition in which loxoprofen or a salt thereof and diphenylpyrine or a salt thereof are arranged so as not to contact each other depending on the components constituting the solid composition of the above (provided that component (A) is loxoprofen or a salt thereof itself, And the component (B) is diphenylpyrine or a salt thereof). 固形製剤である請求項1〜13いずれか1項記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 to 13, which is a solid preparation. 剤形が、カプセル剤、丸剤、顆粒剤、細粒剤、散剤又は錠剤である請求項1〜14いずれか1項記載の医薬組成物。 The pharmaceutical composition according to any one of claims 1 to 14 , wherein the dosage form is a capsule, pill, granule, fine granule, powder or tablet.
JP2012152596A 2011-07-06 2012-07-06 Loxoprofen-containing pharmaceutical composition Active JP5433053B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012152596A JP5433053B2 (en) 2011-07-06 2012-07-06 Loxoprofen-containing pharmaceutical composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011149899 2011-07-06
JP2011149899 2011-07-06
JP2012152596A JP5433053B2 (en) 2011-07-06 2012-07-06 Loxoprofen-containing pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2013032353A JP2013032353A (en) 2013-02-14
JP2013032353A5 true JP2013032353A5 (en) 2013-03-28
JP5433053B2 JP5433053B2 (en) 2014-03-05

Family

ID=47788530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012152596A Active JP5433053B2 (en) 2011-07-06 2012-07-06 Loxoprofen-containing pharmaceutical composition

Country Status (1)

Country Link
JP (1) JP5433053B2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4357016B2 (en) * 1998-11-06 2009-11-04 第一三共株式会社 Pharmaceutical composition containing loxoprofen
JP5232520B2 (en) * 2007-04-17 2013-07-10 第一三共ヘルスケア株式会社 Anti-adenoviral agent containing loxoprofen

Similar Documents

Publication Publication Date Title
JP2012031131A5 (en)
JP2012031147A5 (en)
EA201400173A1 (en) SUSTAINABLE TO DESTRUCTION TABLET THAT PROVIDES IMMEDIATE RELEASE OF MEDICINES
CY1115652T1 (en) DOSAGE FORM THAT CONTAINS TWO ACTIVE MEDICINAL MIXING INGREDIENTS IN DIFFERENT NATURAL FORMS
NZ602442A (en) A fast dissolving pharmaceutical composition
JP2016516058A5 (en)
JP2012533559A5 (en)
PH12014501813A1 (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
MX340188B (en) Manufacturing of active-free granules and tablets comprising the same.
ITMI20050387A1 (en) NEW SOFT JELLY CAPSULES
JP2006342148A5 (en)
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
JP2014527506A5 (en)
JP2012046484A5 (en)
MX2018010065A (en) Oral dosage form comprising rifaximin in form beta.
JP2013032353A5 (en)
MX2022013541A (en) Gamma-polyglutamic acid and zinc compositions.
WO2015022560A8 (en) Stable pharmaceutical composition containing bisoprolol and ramipril
HRP20220701T1 (en) Fused benzazepines for treatment of tourette's syndrome
WO2013130584A3 (en) Formulation containing ws727713
JP2015536999A5 (en)
HRP20161153T1 (en) A pharmaceutical composition comprising aspirin and bisoprolol
WO2008038155A3 (en) Controlled-release pharmaceutical tablets
RU2019122120A (en) ORAL PREPARATION IBUPROFEN
TH116660B (en) Tablet and granulate powder containing 6-fluoro-3-hydroxy-2-pyrazine carboxamide